PDF(Pubmed)
Abstract：
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation of the efficacy and safety of immune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patients who have failed platinum-based chemotherapy, as well as the effect of combined treatment with trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally, the guideline assessed the efficacy and safety of omitting lymph node dissection in low-risk endometrial cancer patients, investigated the effect of sentinel lymph node mapping in early-stage endometrial cancer surgery, addressed the outcome of chemoradiation therapy as a postoperative treatment in patients with advanced (stage III-IVA) endometrial cancer, and explored the impact of initial treatment with immune checkpoint inhibitors on survival in patients with advanced or recurrent endometrial cancer patients.
摘要：
韩国妇科肿瘤学会（KSGO）一直在努力通过制定2021年更新的临床实践指南来标准化和提高国内子宫体癌治疗的质量。KSGO根据文献检索使用4个关键要素修订了指南：人口，干预,比较,结果框架。这些要素包括评估免疫检查点抑制剂治疗在铂类化疗失败的复发/晚期子宫内膜癌患者中的疗效和安全性。以及曲妥珠单抗联合治疗HER2/neu阳性子宫内膜癌患者的效果。此外,该指南评估了低风险子宫内膜癌患者省略淋巴结清扫术的有效性和安全性,探讨前哨淋巴结定位在早期子宫内膜癌手术中的作用，讨论了化疗作为晚期（III-IVA期）子宫内膜癌患者术后治疗的结果，探讨免疫检查点抑制剂初始治疗对晚期或复发子宫内膜癌患者生存率的影响。
